key: cord-0857690-qhitr4oq
authors: Zhao, Yun-Li; Gou, Zhong-Ping; Shang, Jian-Hua; Li, Wan-Yi; Kuang, Yu; Li, Ming-Yuan; Luo, Xiao-Dong
title: Anti-microbial Effects In Vitro and In Vivo of Alstonia scholaris
date: 2021-01-03
journal: Nat Prod Bioprospect
DOI: 10.1007/s13659-020-00294-6
sha: baf5bbb21544117f271997793dfdfa8a0054d9fd
doc_id: 857690
cord_uid: qhitr4oq

Alstonia scholaris could be used as a traditional medicinal plant in China for the treatment of acute respiratory, which might be caused by respiratory tract infections. The investigation tested the anti-infective effects of total alkaloids extract (TA) from leaves of A. scholaris, and as a result, TA inhibited herpes simplex virus type 1 (HSV-1), respiratory syncytial virus (RSV) and influenza A virus (H1N1) in vitro respectively. In addition, the survival days of mice were prolonged, and the lung weights and mortality of mice were decreased significantly, after oral administrated TA in H1N1 and beta-hemolytic streptococcus infectious models in vivo respectively. The finding supported partly the traditional usage of A. scholaris in the treatment of respiratory infections. [Image: see text] SUPPLEMENTARY INFORMATION: The online version of this article (10.1007/s13659-020-00294-6) contains supplementary material, which is available to authorized users.

Acute respiratory infections (ARIs) are the most common infections in humans, ranged from common cold through to very severe acute respiratory syndrome. ARIs are caused by over 200 viruses or bacteria [1] . Respiratory viruses seem to cause or serve as a co-pathogen in most cases of ARIs in epidemiologic studies. The specific viruses most frequently associated with acute bronchitis, in order of frequency of occurrence, are influenza, parainfluenza, respiratory syncytial virus (RSV), coronavirus, herpes simplex virus (HSV), adenovirus, and rhinoviruses [2] . The upper airway is a major ecological reservoir of bacterial species, bacterial infection ARIs approximately accounts for 15% of all patients, most of which are hemolytic streptococcus, followed by haemophilus influenzae, pneumococcus and staphylococcus, and occasionally gram-negative bacill [3] .

Antiviral drugs and antibiotics are commonly used to treat ARIs in clinic, however, increasing drug resistance, toxicity, side effects, are formidable problems [4] . Therefore, alternative effective modalities for the treatment of respiratory infections are needed. And there is a growing recognition of the herbal medicine as its effectiveness has been investigated scientifically and a long history of native medicine [5] .

Alstonia scholaris (L.) R. Br., an evergreen tree of Apocynaceae, is widely distributed in southwestern China, India, Thailand, Malaysia, Philippines, Africa, Australia, etc. [6] . In traditional medicine, the leaf of A. scholaris has been also used for treatment of many acute and chronic respiratory disorders for centuries [7] [8] [9] [10] . The total alkaloids extract (TA) was obtained from the leaves of A. scholaris by extraction with ethyl acetate, and indole alkaloid content was more than 50%. Various laboratory-identified biological activities have been reported by our research group, including antitussive, anti-asthmatic, expectorant [11] , analgesic, anti-inflammatory [12] , anti-airway inflammation [13] , anti-allergic asthma [14] , anti-postinfectious cough [15] , alleviating emphysema [16] and pulmonary fibrosis [17] . The anti-inflammatory effects were achieved by triggering the β 2 adrenergic receptor [18] and inhibiting the nuclear factor-κB expression [19] . In addition, preclinical safety evaluation results indicated that TA had a wide safety range in rats [20] or dogs [21] and no genotoxic effects [22] . Notably, the human pharmacokinetic results [23] were consistent with those of preclinical studies [14, 24] , and the four principal alkaloids (picrinine, scholaricine, vallesamine, and 19-epischolaricine, Fig. 1 ) were all distributed in blood, thus ensuring credibility and validity for further study.

In addition, the chemical components of different parts of the herb were intensively investigated by our group . In the leaves of this plant, picrinine, scholaricine, vallesamine, and 19-epischolaricine were proved to be the major bioactive alkaloids. TA extracted from A. scholaris leaves was approved as a new botanical drug (No. 2011L01436) by the China Food and Drug Administration, due to its strong pharmacological activity, low toxicity, and stable extraction process. Herein, we described antiviral (RSV, HSV-1, H1N1) and anti-bacterial (beta-hemolytic streptococcus) property in vitro and in vivo of TA, which might cause acute respiratory infections clinically. 

As shown in Table S1 , the CPE of RSV and HSV-1 on Hep 2 and Vero cells at 10 -13 , 10 -12 , 10 -11 and 10 -10 groups were 25-70% of normal group, suggesting the RSV and HSV-1 preparations met the virulence criteria for a successful model of HSV-1 infection. The TCID 50 of RSV and HSV-1 were 10 -12 and 10 -11 , respectively. In subsequent experiments, 100 folds TCID 50 /mL of RSV and 10 folds TCID 50 / mL of HSV-1 solution were selected.

As shown in Table S2 , the cell viability of TA on Hep 2 and Vero cells was pretty much the same, the TC 50 value and TC 0 was 18.75 and 6.25 mg/mL, respectively. They were all 1.25 (TC 50 ) and 0.313 (TC 0 ) mg/mL for ribavirinc and acyclovird.

The antiviral activity of TA extracted from A. scholaris was evaluated against RSV and HSV-1 by CPE inhibition assay (Table 1) . Compared with control group, nearly all cells in RSV and HSV-1 alone group were dead (data not shown). Compared with RSV and HSV-1 alone group, TA exhibited satisfied anti-RSV and anti-HSV-1 activity, the un-infected cells in TA groups was significantly increased in a dose-dependent manner, and the IC 50 value was 3.13 and 1.56 mg/mL, the TI was 6 and 12, respectively. Positive control, ribavirinc and acyclovird also exhibited strong antiviral activity, with IC 50 values ranging from 0.02 (ribavirinc) to 0.01 mg/mL (acyclovird), and the TI value was 62.5 and 125, respectively.

The chicken embryos were treated with TA in a dosedependent manner to determine HI. As shown in Table 2 , strong anti-H1N1 activity of TA was observed, with HI values (50 mg/mL: 1/160; 25 mg/mL: 1/320; 12.5 mg/mL: 1/480, respectively) comparable to that of control (Kugan granule, 1/160). 

To further study the ability of TA to block H1N1 infectivity in vivo, we used a well-known mouse model of nasal H1N1 infection. Table S3 showed the LD 50 of H1N1 was 1/200. Consequently, for the following experiments, mice were intranasally infected with 10 times LD 50 of the virus. As shown in Table 3 , infection with 10 times LD 50 of H1N1 led to the death of all mice of model group within 14 days. Mice showed signs of piloerection, lethargy, weight loss and reduced food intake 3 days after H1N1 inoculation, and some of them died within 7-10 days of infection. Table 3 showed that the survival rate was 0% in the virus model group, but increased to 73.3%, 76.7% and 66.7% on 14 d in 50, 25 and 12.5 mg/kg of TA groups, respectively. Meantime, the mean survival time of model group was 7.0 ± 2.3 days only, whereas, it was significantly prolonged to 12.27 ± 3.02, 12.37 ± 3.17 and 11.63 ± 3.61 days (all p < 0.01), the elongation ratio increased by 75.3%, 76.7 and 66.1% after the oral intervention of TA (50, 25 and 12.5 mg/kg).

In addition, weight of lung tissues was determined to verify whether TA could protect against H1N1 induced pulmonary injury. The lung weight in the model group (0.30 ± 0.035 g) was increased compared to the normal group (0.17 ± 0.016 g), indicating that H1N1 infection could cause swelling of lung tissues. Expectedly, it was showed a significant decrease of lung tissue weight in three doses of TA, and the average weights of lungs were 0.21 ± 0.015 g, 0.22 ± 0.015 g, and 0.23 ± 0.015 g compared with the virus-infected model group (0.30 ± 0.035 g, p < 0.01). Notably, the inhibitory effect of TA was comparable to control. Therefore, the minimum effective dose (MED) of TA against influenza A virus in Balb/C mice was 12.5 mg/kg and the TI was 64.

As shown in Table S4 , the MLD of beta-hemolytic streptococcus was determine to be 1 × 10 9 CFUs on female KM mice. Thus, for the follow-up experiments, mice were intraperitoneally infected with MLD of the pathogen. Survivors of mice were recorded daily for 7 days postchallenge and shown as percentage of animal's survival ( Table 4 ). The mortality of model group was 100%, while treatment with TA increased the survival from 0 to 40% at all does (400, 200, 100, 50, 25, 12.5 mg/kg), in a non-dose dependent manner, and the ED 50 value was 83.291 mg/kg. Hence, the TI value was calculated as 65.793 by the formula. Amoxicillin, the standard drug used in this experiment, reduced mice mortality by 0%.

TA, an alkaloids extract from leaves of A. scholaris, commonly was used for treating the acute upper respiratory infection in traditional Chinese medicine. It was shown to reduce the numbers of neutrophil and leukocytes, induced by lipopolysaccharide infection and significantly attenuate histopathological changes and excessive secretion of inflammatory cytokines in an airway inflammation rat model.

In present paper, we reported the anti-infective activities of TA that may provide effective therapeutic approaches to the treatment of diseases such as infections of herpes simplex virus (HSV), respiratory syncytial virus (RSV) and influenza A/PR/8/34 (H1N1) virus. HSV, a double stranded DNA virus belonging to the herpesviridae family, involves two human antigen types, HSV-1 and HSV-2 [46] . Clinical manifestations of this viral infection range from benign to severe and life-threating syndromes in immunocompromised patients. In present study, the inhibitory effects of TA against HSV-1 were manifested as a marked reduction in cytopathic Human respiratory syncytial virus (RSV), an Orthopneumovirus belonging to the Pneumoviridae family, is one of the most important pathogens causing severe acute lower respiratory infections [47] . The clinical manifestations after RSV infection range from a mild upper respiratory tract infection to severe life-threatening lower respiratory tract involvement such as bronchiolitis, pneumonia, and croup, together with some common symptoms including fever, rhinorrhea, cough, and wheezing [48] , which are not readily distinguished from those of other common respiratory virus infections. As expected, the replication of RSV was inhibited by the intervention of TA in vitro, the IC 50 and TI against RSV were 3.13 mg/mL and 6, respectively.

Influenza A virus, one of the most infectious influenza viruses, contains an eight-segmented negative sensed RNA that codes a total of 14 different proteins [49] . These viral proteins facilitate the virus replication inside the target cell, exploit the host immune system and intracellular pathway store plicate and prompt the releasing of newly formed viral particles from the infected cell [50] . It has been reported that the fatal consequence of the influenza is eminently associated with acute pneumonia which could destabilize the atherosclerotic plaque in the arteries, increasing the risk of heart attack and stroke [51] . The H1N1 virus replication was greatly suppressed in the presence of TA, and the hemagglutination titer was significantly reduced from 1/1280 to 1/160.

In vivo testing without doubt is one of the recognized, if not the most important, essential links between in vitro sensitivity testing and clinical studies. In fact, several guide lines for the clinical evaluation of efficacy and toxicity of anti-infective drugs explicitly require experimental evaluation of new compounds (or novel combinations or therapeutic modalities) in animals as prerequisites for clinical trials [52, 53] . Following, we investigated the protective effect of TA against the H1N1 virus in a mice model by intranasal inoculation virus suspension. Importantly, oral administration of 50, 25, 12.5 mg/kg TA possessed effective antiviral activity in infected-mice, conferring 73.3%, 76.7% and 66.7% protection from death against H1N1, which was superior to those of Kugan granule (66.7%). TA also prolonged survival time and decreased lung weights in virus-infected mice. Taken together, the antiviral effects of TA against influenza virus were demonstrated in this study, which agrees with findings of previous studies [54] .

Moreover, upper respiratory infection caused by virus can easily lead to secondary infections caused by bacteria. Beta-hemolytic streptococcus is one of the major human pathogens that cause both community-and hospital-acquired infections [55] . The infections caused by it ranged from the relatively mild superficial skin purulent inflammation to the more serious conditions as respiratory tract infection, epidemic pharyngitis, neonatal sepsis, bacterial endocarditis, scarlet fever, rheumatic fever and glomerulonephritis [56] . First of all, the upper respiratory tract mucous membrane was damaged by beta-hemolytic streptococcus and its discharge toxins, with the symptoms of pharyngeal hyperemia, edema. Furtherly, local inflammatory cell infiltration and seepage resulted in redness and swelling of the pharynx, tonsil, soft palate and even uvula. Eventually, tonsil and soft palate mucosa often undergo necrosis and develop into purulent pharyngeal buccal inflammation and tonsils.

Dose bacteria pathogenicity experiments were conducted to determine the MLD of the pathogen beta-hemolytic streptococcus infection in mice. The MLD 50 was 1 × 10 9 CFUs in female mice. Therefore, for subsequent experiments, mice were infected with MLD of the pathogen by intraperitoneal injection. In particular, TA, at all the doses tested, effectively protected the mice from infected by beta-hemolytic streptococcus and increased animal survival rate, thus establishing Normal  20  0  0  0  0  100  Model  20  11  8  1  0  0  Amoxicillin -300  20  0  0  0  0  100  TA-400  20  8  3  1  0  40  TA-200  20  11  2  0  0  35  TA-100  20  12  3  0  0  25  TA-50  20  16  2  0  0  10  TA-25  20  14  3  0  0  15  TA-12.5  20  17  1  0  0  10 the potential in vivo antibacterial activity of TA and further supporting its traditional use in the treatments of ARIs. 

Dried and powdered leaves of A. scholaris were extracted with 90% ethyl alcohol under reflux conditions (3 h × 4 times) at room temperature, and the solvent was evaporated in vacuo to obtain the ethanolic extract. The ethanolic extract was dissolved in 0.3% aqueous HCl solution and filtered; the residue was the nonalkaloid fraction. Then, the acidic solution, adjusted to pH 9-10 with 10% aqueous ammonia, was extracted with ethyl acetate to obtain the total alkaloids (TA) fraction (batch no. 20070512, 20111101).

Acyclovir and ribavirin were selected to be antiviral control against HSV-1 and RSV and provided by Tianjin Pharmaceutical Jiaozuo Co, Ltd (Tianjin, China). Kugan granule, a launched traditional Chinese medicine formula, was used to be antiviral control against H1N1, and provided by Qingdao Guofeng Pharmaceutical Co. Ltd (Qingdao, Shandong). 

Specific-pathogen-free, female, Balb/C and KM mice (weight: approximately 20 g) were purchased from West China Medical Laboratory Animal Center, Sichuan University (license number SCXK [Chuan] 3-042-2010). Our experiments were approved by the Institutional Animal Care and Use Committee of the Sichuan University and performed according to the international rules concerning animal experiments and the internationally accepted ethical principles for the use and care of laboratory animals.

The anti-RSV and anti-HSV-1 activities of TA were determined by the titer reduction assay as previously described [57] . Briefly, Hep2 (to RSV) and Vero cell monolayers (to HSV-1) were co-incubated with a series of virus concentrations from 10 -3 to 10 -13 . The cytopathogenic effect (CPE) was observed and half of tissue culture infective dose (TCID 50 ) was calculated according to Reed & Muench formula [58] .

The half toxicity (TC 50 ) and non-cytotoxic concentration (TC 0 ) of TA against Hep2 and Vero cells were determined using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay as previous [59] .

Methods was referred to the previous with minor modifications [60] , TA was suspended in 1% dimethylsulfoxide/sterile water for injection. Equivalent of 100 folds TCID 50 /mL of RSV for Hep2 cells and 10 folds TCID 50 /mL of HSV-1 for Vero cells were added to the cell cultures which were then incubated at 37 °C in a 5% CO2 atmosphere, and the supernatant was removed after incubation for 2 h. Cells were then treated with serial concentrations of TA diluted from TC 50 to 1/64 TC 50 (mg/mL) or with two-fold serial dilutions of ribavirin and acyclovir (from 1/2 TC 50 to 1/128 TC 50 ) used as the positive control. All wells were then observed under a light microscope to determine the virus-induced cytopathic effect (CPE) at day 5 after the treatment. The concentrations of the test articles that reduced CPE by 50% (IC 50 ) were determined. And the therapeutic index (TI) value was calculated as the ratio TC 50 /IC 50 [61] .

The efficacy of TA against H1N1 virus in vitro was studied by cultivation of chicken embryo and haemagglutination inhibition test as previously reported [62] . The proliferative activity of influenza virus H1N1 was determined by chicken embryo method and the virus titers was 1/1280. All embryonated eggs except the normal group were injected with 0.1 mL H1N1 virus (60 U/mL) via allantoic cavity inoculation before treatment. Then the eggs inoculated virus were randomly divided into 5 groups. The embryonated eggs in model group received 0.1 mL of 1% DMSO, the embryonated eggs in the positive group received 0.1 mL of control; group 3 to 5 were administrated different concentrations of TA treatment, and finally, the normal group was also inoculated with 0.1 mL of 1% DMSO. The concentration of TA was non-toxic to chicken embryos confirmed by a preliminary experiment (data not shown). Allantoic fluid of chicken embryo were collected from each group at 48 h post infection, and the hemagglutination titer (HI) was determined by hemagglutination assay with 1% chicken red blood cell. The virus titer of H1N1 declined by one dilution was considered to be effective, and significant effect by two dilutions, when compared the model group.

A preliminary examination was carried out before the formal experiment began to determine the virulence of H1N1 virus on mice. For infectious experiment, 60 eight weeks BALB/c female mice were divided into six groups including normal (mice without viral infection); model (infected mice); control (Kugan granule, 960 mg/kg) and TA-treated groups (50, 25, 12.5 mg/kg). The choice of the doses used in this experiment was based on the pilot study [63] and the results from acute oral toxicity study [20] . The treatment started 2 days before viral challenge. Accordingly, treatment of the mice with TA or positive control started two days before infectious. For the normal and model group, the mice were given 1% DMSO instead. Subsequently, all mice except the normal group were challenged with 10 times LD 50 of H1N1 by intranasal inoculation of 30 μL of virus suspension. An equal volume of intranasal saline was substituted for the normal group. Following viral, the treatment was repeated daily for 14 consecutive days and survival animals were recorded for 14 days, and the lungs were then collected and weighted.

The minimum lethal dose (MLD) was regarded as the minimum amount of infectious bacteria that caused all the infected animals to die within 1-2 days after the intraperitoneal injection of beta-hemolytic streptococcus suspension [64] . Briefly, forty-five female KM mice were randomly divided into nine groups (each group of five). Then, forty animals in different groups were administrated intraperitoneally with beta-hemolytic streptococcus suspension (10 10 -10 3 /mL) at a volume of 0.5 mL/mouse. Normal animals were given the same volume of saline solution.

As for the protection against beta-hemolytic streptococcus in vivo, the mice were divided into nine groups of ten mice each: normal (mice without bacterial infection); model (infected mice); amoxicillin-treated group (positive control, 300 mg/kg) and six TA-treated groups (400, 200, 100, 50, 25, 12.5 mg/kg). The oral treatment was administered two days prior to infection. For normal and model groups, 1% DMSO was administered by oral gavage. Subsequently, the bacteria-infected groups except normal group were inoculated intraperitoneally with MLD of 0.5 mL of beta-hemolytic streptococcus suspension. For the normal group, the mice were given the same volume saline water in place of the bacterial suspension. Following bacterial challenge, the treatment was repeated one time after infectious. The clinical signs and surviving animals were recorded daily till 7 days post-infection. Half of the effective dose (ED 50 ) was calculated using Bliss method, and then the therapeutic index (TI) at each test was determined using the following formula: TI = LD 50 /ED 50 (LD 50 : half of the lethal dose, 5.48 g/kg).

Data from the experiment are expressed as the mean ± standard deviation of the mean. Two-tailed Mann-Whitney U test was used for comparing between two groups, one-way analysis of variance with least significant difference or Kruskal-Wallis analysis with Dunn post-test for multiple comparisons and chi-square test, in which nonparametric analyses were appropriate. Analyses were performed using the Prism software (GraphPad, San Diego, CA, USA). A p-value < 0.05 denoted statistical significance in all analyses.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.

Handbook of Animal Models of Infection: Experimental Models in Antimicrobial Chemotherapy